0000899243-20-017877.txt : 20200630
0000899243-20-017877.hdr.sgml : 20200630
20200630064120
ACCESSION NUMBER: 0000899243-20-017877
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200625
FILED AS OF DATE: 20200630
DATE AS OF CHANGE: 20200630
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Khuong Chau Quang
CENTRAL INDEX KEY: 0001609405
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 201000374
MAIL ADDRESS:
STREET 1: C/O ORBIMED ADVISORS
STREET 2: 601 LEXINGTON AVENUE, 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001805890
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
BUSINESS PHONE: 289-799-0891
MAIL ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-25
0
0001805890
Fusion Pharmaceuticals Inc.
FUSN
0001609405
Khuong Chau Quang
C/O FUSION PHARMACEUTICALS INC.
270 LONGWOOD ROAD SOUTH
HAMILTON
A6
L8P 0A6
ONTARIO, CANADA
1
0
0
0
Warrants to Purchase Class B Preferred Shares
1.1514
2020-01-10
4
A
0
359377
0.00
A
2020-01-10
2022-01-10
Common Shares
67311
359377
I
See Footnote
Class B Preferred Shares
2020-06-02
4
P
0
5939025
1.1514
A
Common Shares
1112385
11878051
I
See Footnote
Stock Option (Right to Buy)
17.00
2020-06-25
4
A
0
30000
0.00
A
2030-06-18
Common Shares
30000
30000
D
Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares will become warrants to purchase Common Shares at an exercise price of $8.10 per share.
OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VII, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein, if any.
The Class B Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class B Preferred Shares will convert into the number of Common Shares shown in column 7. The Class B Preferred Shares have no expiration date.
This option shall vest and become exercisable in 36 equal monthly installments commencing on July 18, 2020.
/s/ John Crowley, Attorney-in-Fact
2020-06-29